press releases

Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting
Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting 150 150 Lysogene

• Promising efficacy data in young patients with persistent increase or stabilization in 3 main…

Lysogene Reports its Cash Position as of 31 March 2022
Lysogene Reports its Cash Position as of 31 March 2022 150 150 Lysogene

Cash and cash equivalents of €10.7 million[1] as of 31 March 2022 Paris, France —…

Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome
Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome 150 150 Lysogene

Paris, France — 21 April 2022 at 08:00 am CEST — Lysogene (FR0013233475 – LYS),…

Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance phase 2/3 clinical trial with gene therapy LYS-SAF302 for the treatment of MPSIIIA
Lysogene Provides Update on Efficacy, Safety and Timelines of the AAVance phase 2/3 clinical trial with gene therapy LYS-SAF302 for the treatment of MPSIIIA 150 150 Lysogene

Topline data of the main cohort of AAVance clinical trial expected in Q3 2022Stabilization or…

Lysogene Provides Medical Update
Lysogene Provides Medical Update 150 150 Lysogene

Third patient treated in the global clinical trial with LYS-GM101 gene therapy program in GM1…

Lysogene Reports its Cash Position as of 31 December 2021
Lysogene Reports its Cash Position as of 31 December 2021 150 150 Lysogene

Cash and cash equivalents of €12.3 million[1] as of 31 December 2021 Paris, France —…

Lysogene announces termination of license agreement with Sarepta for LYS-SAF302 program, regaining global commercial rights
Lysogene announces termination of license agreement with Sarepta for LYS-SAF302 program, regaining global commercial rights 150 150 Lysogene

Lysogene remains focused on developing its pipeline led by LYS-SAF302, LYS-GM101, Fragile X and other…

Half-Year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux
Half-Year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux 150 150 Lysogene

Paris, France — 5 January 2022 at 06:00pm — Lysogene (FR0013233475 – LYS), a phase 3…

Lysogene Enters into a Loan Agreement of €15 million with the European Investment Bank (EIB)
Lysogene Enters into a Loan Agreement of €15 million with the European Investment Bank (EIB) 150 150 Lysogene

The financing will enable Lysogene to accelerate the development of its gene therapy platformThe loan…

Lysogene awarded Innovation Passport by the UK MHRA for the GM1 gangliosidosis program
Lysogene awarded Innovation Passport by the UK MHRA for the GM1 gangliosidosis program 150 150 Lysogene

First step in the recent UK MHRA initiative to accelerate the development and access to…

Lysogene COVID-19 update

Find out More

Lysogene is developing therapies for children with CNS diseases.

Delivering Gene Therapy’s Promise

About Us
Our Science
Meet the Team
Diseases
Resources

Contact Us
Careers
Transparency
Compassionate Use Policy

©2022 Lysogene. All rights reserved.

Cookie Policy
Privacy Policy
Legal Notice

Get In Touch

Don’t hesitate to contact us if you need more help.

    Start Typing